Hypothyroidism and Thyroid Disorders in Pregnancy

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/15

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering definition criteria, etiology, maternal-fetal risks, clinical features, dosing guidelines, and management protocols for thyroid disorders during pregnancy.

16 Terms

1
New cards

Overt Hypothyroidism

A clinical condition defined biochemically by an elevated thyroid-stimulating hormone level (↑TSH\uparrow\text{TSH}) combined with a low free thyroxine level (Low FT4\text{Low } FT_4).

2
New cards

Hashimoto's Thyroiditis

An autoimmune disorder identified as the leading cause of primary hypothyroidism, marked by positive thyroid peroxidase (TPO-Ab\text{TPO-Ab}) and thyroglobulin (TG-Ab\text{TG-Ab}) antibodies.

3
New cards

Subclinical Hypothyroidism (SCH)

A condition defined biochemically by elevated levels of TSH\text{TSH} between 2.5 mU/L2.5\,mU/L and 10 mU/L10\,mU/L alongside normal circulating concentrations of free thyroxine (FT4FT_4).

4
New cards

Isolated Hypothyroxinaemia (IH)

A state characterized by normal TSH\text{TSH} levels but low FT4FT_4 levels, defined as either below the reference range or between the 2.5th2.5^{\text{th}} and 10th10^{\text{th}} centile of the normal pregnant population.

5
New cards

Target TSH in Pregnancy

The biochemical therapeutic goal of achieving TSH≤2.5 mU/L\text{TSH} \le 2.5\,mU/L (or <2.5 mU/L< 2.5\,mU/L) with normal FT4FT_4 levels prior to conception and throughout antenatal care by titrating levothyroxine.

6
New cards

Empiric Levothyroxine Adjustment upon Pregnancy Confirmation

An immediate empiric dose escalation of approximately 25%25\% upon confirmation of pregnancy, achieved by doubling the daily dose 2 days per week2\,\text{days per week}, or increasing daily intake by 25 μg/day25\,\mu g/\text{day} (if baseline dose ≤100 μg\le 100\,\mu g) or 50 μg/day50\,\mu g/\text{day} (if baseline dose >100 μg> 100\,\mu g).

7
New cards

Initial Levothyroxine Dose for Overt Hypothyroidism

The recommended full replacement starting dose for pregnant patients newly diagnosed with overt hypothyroidism, calculated as 1.6 μg/kg/day1.6\,\mu g/kg/\text{day}.

8
New cards

Initial Levothyroxine Dose for Subclinical Hypothyroidism (ETA)

The starting dosage recommended by the European Thyroid Association for newly diagnosed subclinical hypothyroidism in pregnancy, calculated as 1.2 μg/kg/day1.2\,\mu g/kg/\text{day} with a target TSH<2.5 mU/L\text{TSH} < 2.5\,mU/L.

9
New cards

Antenatal Thyroid Monitoring Protocol

The clinical monitoring schedule requiring baseline TSH\text{TSH} and FT4FT_4 assessment, follow-up testing every 4−6 weeks4-6\,\text{weeks} until 20 weeks20\,\text{weeks} of gestation, and a subsequent check at 28 weeks28\,\text{weeks}.

10
New cards

Postpartum Medication Management (Pre-existing Hypothyroidism)

The protocol directing that maternal levothyroxine dosages increased during gestation should be returned to pre-pregnancy baseline levels at 2 weeks2\,\text{weeks} postpartum.

11
New cards

Postpartum Medication Management (Gestational Diagnosis)

The protocol directing that women first prescribed levothyroxine during pregnancy discontinue treatment postpartum and obtain thyroid function tests (TFT) at 6 weeks6\,\text{weeks} after delivery.

12
New cards

Thyroid Peroxidase Antibodies (TPO-Ab)

Autoantibodies directed against thyroid peroxidase; when present, they indicate a higher risk of gestational complications and necessitate vigilant postpartum monitoring for postpartum thyroiditis.

13
New cards

Maternal Complications of Hypothyroidism

Adverse maternal outcomes associated with untreated disease, including subfertility secondary to anovulation, cardiac dysfunction, pregnancy-induced hypertension (PIH), gestational diabetes, placental abruption, and preterm delivery.

14
New cards

Fetal and Neonatal Complications of Hypothyroidism

Adverse offspring risks including intrauterine growth restriction (IUGR), intrauterine fetal demise (IUFD), miscarriage, increased neonatal death, NICU admission, neonatal hypothyroidism, and low IQ due to insufficient T4T_4 essential for fetal neurodevelopment.

15
New cards

Overt Thyrotoxicosis in Pregnancy

A condition occurring in 0.2%−0.4%0.2\% - 0.4\% of pregnant women, characterized biochemically by suppressed TSH\text{TSH} levels and elevated FT4FT_4 levels outside the pregnancy-specific reference range.

16
New cards

Graves' Disease in Pregnancy

An autoimmune hyperthyroid condition representing the most frequent cause of gestational thyrotoxicosis, occurring with a prevalence of 0.2%0.2\% during pregnancy.